Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 3, 2014, Pages 227-237

  Kujal, Petr ^a   Čertíková Chábová, Vera ^a   Škaroupková, Petra ^a   Husková, Zuzana ^a   Vernerová, Zdena ^a   Kramer, Herbert J ^b   Walkowska, Agnieszka ^c   Kompanowska Jezierska, Elzbieta ^c   Sadowski, Janusz ^c   Kitada, Kento ^d   Nishiyama, Akira ^d   Hwang, Sung H ^e   Hammock, Bruce D ^e   Imig, John D ^f   Cervenka L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF BONN   (Germany)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d KAGAWA UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

5 6 nephrectomy; Chronic kidney disease; Cytochrome P450 enzymes; End organ damage; Epoxyeicosatrienoic acids; Hypertension; Renin angiotensin system; Soluble epoxide hydrolase

Indexed keywords

4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ANGIOTENSIN II; DIHYDROXYICOSATRIENOIC ACID; DRINKING WATER; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; LOSARTAN; LOZAP; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEGRADATION; DISEASE COURSE; ENZYME INHIBITION; FEMALE; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY PARENCHYMA; KIDNEY TUMOR; LONG TERM CARE; MALE; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; RAT MODEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHAM PROCEDURE; SURVIVAL RATE; TISSUE LEVEL;

5/6 NEPHRECTOMY; CHRONIC KIDNEY DISEASE; CYTOCHROME P450 ENZYMES; END-ORGAN DAMAGE; EPOXYEICOSATRIENOIC ACIDS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; SOLUBLE EPOXIDE HYDROLASE;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; EPOXIDE HYDROLASES; FEMALE; HYPERTENSION; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 84896322811     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12204     Document Type: Article

References (61)

1. US Renal Data System. USEDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. 2012.
2. Brenner BM. Nephron adaptation to renal injury or ablation. Am. J. Physiol. 1985; 249: F324-37.
3. Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: Insight from animal models. Curr. Opin. Nephrol. Hypertens. 2006; 15: 250-7.
4. Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin. Nephrol. 2003; 23: 194-9.
5. Hostetter TH, Olson JL, Rennke HG, Ventatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to ablation. Am. J. Physiol. 1981; 241: F85-93.
6. Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am. J. Pathol. 1975; 79: 95-106.
7. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Micros. Res. Tech. 2002; 57: 189-95.
8. Macconi D. Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol. Histopathol. 2010; 25: 655-68.
9. Kohan DE. Endothelin, hypertension and chronic kidney disease: New insight. Curr. Opin. Nephrol. Hypertens. 2010; 19: 134-9.
10. Briet M, Burns KD. Chronic kidney disease and vascular remodeling. Molecular mechanisms and clinical implications. Clin. Sci. 2012; 123: 399-416.
11. Vanecková I, Kujal P, Husková Z et al. Effects of combined endothelin a receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press. Res. 2012; 35: 382-92.
12. Kujal P, Certíková Chábová V, Vernerova Z et al. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: Are there blood pressure-independent effects? Clin. Exp. Pharmacol. Physiol. 2010; 37: 1159-69.
13. Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr. Opin. Nephrol. Hypertens. 2013; 22: 1-9.
14. Ptinopolou AG, Pikilidou MI, Lasaridis N. The effect of antihypertensive drugs on chronic kidney disease: A comprehensive review. Hypertens. Res. 2013; 36: 91-101.
15. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney Int. 2012; 81: 351-62.
16. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006; 17: 2985-91.
17. Berl T. Renal protection by inhibition of the renin-angiotensin-aldosterone system. J. Renin Angiotensin Aldosterone Syst. 2009; 10: 1-8.
18. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J. Am. Soc. Nephrol. 1994; 5: 1139-46.
19. Gordon J, Kopp JB. Off the beaten renin-angiotensin-aldosterone system pathway: New perspectives on antiproteinuric therapy. Adv. Chronic Kidney Dis. 2011; 18: 300-11.
20. Lattanzio MR, Weir MR. Does blockade of the renin-angiotensin-aldosterone system slow progression of all forms of kidney disease? Curr. Hypertens. Rep. 2010; 12: 369-77.
21. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent response. Pfugers Arch. 2010; 459: 881-95.
22. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 2012; 92: 101-30.
23. Capdevilla J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr. Opin. Nephrol. Hypertens. 2013; 22: 163-9.
24. Elmarakby AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012; 302: R321-30.
25. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front. Biosci. 2008; 13: 3480-7.
26. Huang H, Morisseau C, Wang JF et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. Renal Physiol. 2007; 293: F342-9.
27. Sporková A, Kopkan L, Varcabová A et al. Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 300: R1468-75.
28. Neckár J, Kopkan L, Husková Z et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-I-ylureido) cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin. Sci. 2012; 122: 513-25.
29. Honetschlägerová Z, Husková Z, Vanourkova Z et al. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J. Physiol. 2011; 589: 207-19.
30. Kopkan L, Husková Z, Sporková A et al. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press. Res. 2012; 35: 595-607.
31. Honetschlägerová Z, Sporková A, Kopkan L et al. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2011; 29: 1590-601.
32. Honetschlägerová Z, Kitada K, Husková Z et al. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with l-NAME. J. Hypertens. 2013; 31: 321-32.
33. Zhao G, Tu L, Li X et al. Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis. Hum. Gene Ther. 2012; 23: 688-99.
34. Jung O, Jansen F, Mieth A et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One 2010; 5: e11979.
35. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-4.
36. Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am. Heart J. 2009; 157(Suppl.): S7-16.
37. Čertíková Chábová V, Walkowska A, Kompanowska-Jezierska E et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin. Sci. 2010; 118: 617-32.
38. Williams JM, Murphy S, Burke M, Roman RJ. 20-Hydroxyeicosatetraenoic acid. A new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 2010; 56: 336-44.
39. Ai D, Fu Y, Guo D et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 2007; 104: 9018-23.
40. Ai D, Shyy JYY, Zhu Y. Linking an insect enzyme to hypertension: Angiotensin II-epoxide hydrolase interactions. Kidney Int. 2010; 77: 88-92.
41. Yoshida Y, Fogo A, Shiraga H, Glick AD, Ichikawa I. Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney Int. 1988; 33: 855-67.
42. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J. Clin. Invest. 1988; 82: 322-30.
43. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989; 35: 654-60.
44. Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989; 36: 626-35.
45. Fukuda A, Wickman LT, Vekatareddy MP et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end-stage kidney disease. Kidney Int. 2012; 81: 40-55.
46. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: Epithelial-mesenchymal transition. Hum. Pathol. 2009; 40: 1365-76.
47. Ni H, Chen J, Pan M et al. FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. J. Mol. Histol. 2013; 44: 693-703.
48. Barnes JL, Gorin Y. Myofibroblast differention during fibrosis. Role of NAD(P)H oxidases. Kidney Int. 2011; 79: 944-56.
49. Kopkan L, Husková Z, Vanourková Z et al. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vasc. Pharmacol. 2009; 51: 175-81.
50. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007; 59: 251-87.
51. Husková Z, Vanourková Z, Erbanová M et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J. Hypertens. 2010; 28: 495-509.
52. 1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J. Hypertens. 2006; 24: 2465-72.
53. 1A receptor knockout mice. J. Hypertens. 2008; 26: 1379-89.
54. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin. Sci. 2001; 100: 591-9.
55. Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005; 67: 1913-24.
56. Huskova Z, Kramer HJ, Thumova M et al. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press. Res. 2006; 29: 74-83.
57. Husková Z, Kramer HJ, Vanourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 2006; 24: 517-27.
58. Varcabova S, Huskova Z, Kramer HJ et al. Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin. Exp. Pharmacol. Physiol. 2013; 40: 273-81.
59. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension 2005; 45: 299-310.
60. Nakano Y, Hirano T, Uehara K et al. New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progress to end-stage renal failure. Pathol. Int. 2008; 58: 361-70.
61. Lane PH, Steffes MW, Mauer MS. Estimation of glomerular volume: A comparison of four methods. Kidney Int. 1992; 41: 1085-9.